177Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis

Radiochimica Acta

Volumn 96, Issue 1, 2008, Pages 55-61

  Das, T ^a   Chakraborty, S ^a   Sarma, H D ^a   Banerjee, S ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu; Bone pain palliation; DOTMP; Skeletal metastasis

Indexed keywords

EID: 38549171295     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2008.1464     Document Type: Article

References (37)

1. Volkert, W. A., Hoffman, T. J.: Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269 (1999).
2. McEwan, A. J.: Pain from metastatic bone tumors. In: Nuclear Oncology. (Aktolun, C., Tauxe, W. N., eds.) Springer, Berlin, Heidelberg (1999), p. 245.
3. Hosain, F., Spencer, R. P.: Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Semin. Nucl. Med. 22, 11 (1992).
4. Lewington, V. J.: Cancer therapy using bone-seeking isotopes. Phys. Med. Biol. 41, 2027 (1996).
5. Pandit-Taskar, N., Batraki, M., Divgi, C. R.: Radiopharmaceutical therapy for palliation of bone pain from osseous metastasis. J. Nucl. Med. 45, 1358 (2004).
6. Lewington, V. J.: Bone-seeking radionuclides for therapy. J. Nucl. Med. 46, 38S (2005).
7. Hoskin, P. J.: Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev. 29, 321 (2003).
8. Hoskin, P. J.: Radiotherapy of bone pain. Pain 63, 137 (1995).
9. Atkins, H. L.: Overview of nuclides for bone pain palliation. Appl. Radiat. Isotopes 49, 277 (1998).
10. Bouchet, L. G., Bolch, W. E., Goddu, S. M., Howell, R. W., Rao, D. V.: Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J. Nucl. Med. 41, 682 (2000).
11. Srivastava, S., Dadachova, E.: Recent advances in radionuclide therapy. Semin. Nucl. Med. 31, 330 (2001).
12. 117mSn(4+) diethylenetriamine-pentaacetic acid for radionuclide therapy of bone cancer. J. Nucl. Med. 41, 2043 (2000).
13. th edn., John Wiley and Sons, Inc., New York (1996).
14. Deligny, C. L., Gelsema, W. J., Tji, T. G., Huigen, Y. M., Vink, H. A.: Bone seeking radiopharmaceuticals. Nucl. Med. Biol. 17, 164 (1990).
15. 177Lu for radionuclide therapy. Appl. Radiat. Isotopes 59, 109 (2003).
16. 32P- orthophosphate: implications for therapy of bone pain and bone metastasis. J. Nucl. Med. 41, 941 (2000).
17. Goeckeler W. F., Edwards, B., Volkert, W. A., Holmes, R. A., Simon, J., Winston, D.: Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med. 28, 495 (1987).
18. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl. Med. Biol. 14, 223 (1987).
19. 177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl. Med. Commun. 23, 67 (2002).
20. 153Sm in rats. Appl. Radiat. Isotopes 45, 949 (1994).
21. Sola, G. A. R., Arguelles, M. G., Bottazzini, D. L., Furnari, J. C., Parada, I. G., Rojo, A., Ruiz, H. V.: Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim. Acta 88, 157 (2000).
22. 105Rh-EDTMP and its bone accumulation. Appl. Radiat. Isotopes 52, 211 (2000).
23. Singh, A., Holmes, R. A., Farhangi, M., Volkert, W. A., Williams, A., Stringham, L. M., Ketring, A. R.: Human pharmacokinetics of Samarium-153-EDTMP in metastatic cancer. J. Nucl. Med. 30, 1814 (1989).
24. Serafini, A. N.: Systematic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastases. Quart. J. Nucl. Med. Mol. Img. 45, 91 (2001).
25. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur. J. Nucl. Med. Mol. Imag. 31 (Suppl. 1), S171 (2004).
26. Liu, S., Edwards, D. S.: Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconj. Chem. 12, 7 (2001).
27. Caravan, P., Ellison, J. J., McMurry, T. J., Lauffer, R. B.: Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications. Chem. Rev. 99, 2293 (1999).
28. Louw, W. K., Dormehl, I. C., van Rensburg, A. J., Hugo, N., Alberts, A. S., Forsyth, O. E., Beverley, G., Sweetlove, M. A., Marais, J., Lotter, M. G., van Aswegen, A.: Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl. Med. Biol. 23, 935 (1993).
29. Volkert, W. A., Simon, J., Ketring, A. R., Holmes, R. A., Lattimer, L. C., Corwin, L. A.: Radiolabeled phosphonic acid chelates: Potential therapeutic agents for treatment of skeletal metastasis. Drug Future 14, 799 (1989).
30. Bayouth, J. E., Macey, D. J., Kasi, L. P., Garlich, J. R., MacMillan, K., Dimopoulos, M. A., Champlin, R. E.: Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J. Nucl. Med. 36, 730 (1995).
31. 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J. Nucl. Med. 43, 1383 (2002).
32. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J. Nucl. Med. 47, 534 (2006).
33. Moedrizer, K., Irani, R.: The direct synthesis of α-aminomethyl phosphonic acids. Mannich-type reactions with orthophosphorus acids. J. Org. Chem. 31, 1603 (1966).
34. Awasthi, V., Meinken, G., Springer, K., Srivastava, S. C., Freimuth, P.: Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice. J. Virol. 78, 6431 (2004).
35. Panagi, Z., Beletsi, A., Evangelatos, G., Livaniou, E., Jthakissos, D. S., Avagoustakis, K.: Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int. J. Pharm. 221, 143 (2001).
36. 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg. Med. Chem. 12, 6077 (2004).
37. 177Lu labeled metronidazole for possible use in targeting tumor hypoxia. Radiochim. Acta 94, 375 (2006).